These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 10932599)
1. Laboratory tests for neuroendocrine tumours. Seregni E; Ferrari L; Stivanello M; Dogliotti L Q J Nucl Med; 2000 Mar; 44(1):22-41. PubMed ID: 10932599 [TBL] [Abstract][Full Text] [Related]
2. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Ferrari L; Seregni E; Bajetta E; Martinetti A; Bombardieri E Anticancer Res; 1999; 19(4C):3415-27. PubMed ID: 10629629 [TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414 [TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of neuroendocrine tumours in the gastrointestinal tract]. Rehfeld JF; Friis-Hansen L; Gøtze JP; Hilsted L; Nielsen FC Ugeskr Laeger; 2010 Oct; 172(43):2957-60. PubMed ID: 21040675 [TBL] [Abstract][Full Text] [Related]
5. New and emerging syndromes due to neuroendocrine tumors. Vinik AI; Gonzales MR Endocrinol Metab Clin North Am; 2011 Mar; 40(1):19-63, vii. PubMed ID: 21349410 [TBL] [Abstract][Full Text] [Related]
6. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. Stevenson R; Libutti SK; Saif MW JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561 [TBL] [Abstract][Full Text] [Related]
9. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Ardill JE; O'Dorisio TM Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544 [TBL] [Abstract][Full Text] [Related]
10. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Singh S; Law C Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254 [TBL] [Abstract][Full Text] [Related]
11. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system]. Hörsch D; Sayeg Y; Bonnet R; Kaemmerer D; Presselt N; Baum RP Pneumologie; 2012 Jan; 66(1):44-8. PubMed ID: 22250054 [TBL] [Abstract][Full Text] [Related]
12. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Oberg K; Astrup L; Eriksson B; Falkmer SE; Falkmer UG; Gustafsen J; Haglund C; Knigge U; Vatn MH; Välimäki M; Acta Oncol; 2004; 43(7):617-25. PubMed ID: 15545182 [TBL] [Abstract][Full Text] [Related]
13. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Janson ET; Sørbye H; Welin S; Federspiel B; Grønbaek H; Hellman P; Mathisen O; Mortensen J; Sundin A; Thiis-Evensen E; Välimäki MJ; Oberg K; Knigge U Acta Oncol; 2010 Aug; 49(6):740-56. PubMed ID: 20553100 [TBL] [Abstract][Full Text] [Related]
14. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC; Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060 [TBL] [Abstract][Full Text] [Related]